Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

41.65 +0.57 (+1.39%)
Official Closing Price Updated: 7:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,406,780
Open 41.10
Bid (Size) 41.01 (1)
Ask (Size) 42.35 (1)
Prev. Close 41.08
Today's Range 41.06 - 41.68
52wk Range 34.74 - 47.70
Shares Outstanding 227,985,334
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends
Qiagen NV's (NASDAQ: QGEN) Q3 net sales of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the  
Via Benzinga
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
From Myriad Genetics, Inc.
Via GlobeNewswire

Performance

YTD
-4.58%
-4.58%
1 Month
-3.12%
-3.12%
3 Month
-4.89%
-4.89%
6 Month
+17.16%
+17.16%
1 Year
-6.64%
-6.64%

More News

Read More
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
Via Benzinga
Exposures COVID-19
Will Chart Analysts Notice Bad Omen on Qiagen's Chart
Via Benzinga
Earnings Scheduled For February 6, 2024
Via Benzinga
Earnings Preview: Qiagen
Via Benzinga
Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion
Via Benzinga
Qiagen's Health Odyssey: Expanding In Riyadh And Partnering In Public Projects
Via Benzinga
Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock
Via Benzinga
Where Qiagen Stands With Analysts
Via Benzinga
These Companies Helped The German DAX Index Hit Its All-time High
Via Talk Markets
Analyst Expectations for Qiagen's Future
Via Benzinga
Preview: Qiagen's Earnings
Via Benzinga
Earnings Scheduled For October 30, 2023
Via Benzinga
Analyst Expectations for Qiagen's Future
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
From Bio-Rad Laboratories, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
The 3 Most Promising Biotech Stocks to Buy Now
Via InvestorPlace
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
From QIAGEN N.V.
Via Business Wire
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
From QIAGEN N.V.
Via Business Wire
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
From QIAGEN N.V.
Via Business Wire
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
From QIAGEN N.V.
Via Business Wire
Genetic Technologies Shares Jump After Strategic Alliance With Qiagen
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.